CLDX - Celldex Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue6,7865,4803,586
Cost of Revenue---
Gross Profit6,7865,4803,586
Operating Expenses
Research Development102,726100,171104,381
Selling General and Administrative35,97933,83720,622
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-132,916-129,541-122,430
Income from Continuing Operations
Total Other Income/Expenses Net4,3862,3444,350
Earnings Before Interest and Taxes-128,530-127,197-118,080
Interest Expense---
Income Before Tax-128,530-127,197-118,080
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-128,530-127,197-118,080
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-128,530-127,197-118,080
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-128,530-127,197-118,080